Preclinical testing for teratogenicity and developmental toxicity: Methods and limitations

Therapie

Volumn 57, Issue 2, 2002, Pages 109-114

  Barrow, P C ^a  

^a MDS Pharma Services   (France)

Author keywords

Development; Drugs; Embryotoxicity; Reproductive toxicology; Teratology

Indexed keywords

ANIMAL EXPERIMENT; BIRTH DEFECT; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; PRIORITY JOURNAL; REGULATORY MECHANISM; REPRODUCTIVE TOXICITY; RISK FACTOR; TERATOGENICITY; TOXICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; MUTAGENICITY TESTS;

EID: 0036319925     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Les femmes dans les essais cliniques
2. Toxicologie de la reproduction: Valeurs prédictives des modèles expérimentaux
3. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients
4. Step 4 tripartite harmonised guidelines. Detection of toxicity to reproduction for medicinal products
5. Toxic substances control act test guidelines. Reproductive and fertility effects: Final rule
6. Reproductive and developmental toxicology safety studies
7. Teratogenic potential of valproic acid
8. Maternal valproic acid and congenital tube defects
9. Teratogenic risks of epilepsy and anticonvulsants
10. Peculiarities and possible mode of action of thalidomide
11. Endocrinology
12. Cardiovascular active drugs
13. Effects of coffee and caffeine on fertility, reproduction, lactation, and development. Review of human and animal data
14. Pharmacokinetic/pharmacodynamic approaches for developmental toxicity
15. Functional toxicity in the developing heart, lung and kidney
16. Historical data of reproductive and developmental toxicity studies in cynomolgus monkeys (Macaca fascicularis)